

The beneficial effects of RAS Blockades on insulin sensitivity, metabolic cytokines and glycemic control in non-diabetic patients: a meta-analysis

Sai Tian¹, Rong Huang², Ke An², and Shaohua Wang³

¹Affiliated Zhongda Hospital of Southeast University

²Southeast University

³ZhongDa Hospital of Southeast University

May 6, 2020

Abstract


Background: To investigate the comparative effects of Renin-Angiotensin System (RAS) Blockades and other antihypertensive agents on insulin sensitivity, metabolic cytokines and glycemic control in non-diabetic patients. **Methods:** We searched for the relevant articles published on MEDLINE, EMBASE, Cochrane Library and Web of Science. 29 randomized control trials that investigated the use of Angiotensin-converting enzyme inhibitors (ACEI) or Angiotensin receptor blockers (ARB) versus active comparator or placebo to determine the effects on insulin sensitivity and glycemic index in non-diabetics were included. Subgroup and meta-regression analyses were performed to explore potential sources of heterogeneity. **Results:** RAS Blockades significantly decreased the homeostasis model assessment of insulin resistance and fasting plasma glucose (WMD -0.69, 95% CI -1.01 to -0.38, p < 0.001; WMD -0.09 mmol/L, 95% CI -0.15 to -0.03, p = 0.003, respectively), while increased the quantitative insulin sensitivity check index (WMD 0.02, 95% CI 0.01 to 0.03, p < 0.001) among non-diabetic patients. Besides, RAS Blockades significantly decreased hsCRP and TNF- α (WMD -0.41 mg/L, 95% CI -0.70 to -0.11, p = 0.007; WMD -0.21 ng/mL, 95% CI -0.30 to -0.13, p < 0.001, respectively), while increased adiponectin and potassium (WMD 0.46 μ g/mL, 95% CI 0.14 to 0.78, p = 0.005; WMD 0.24 mmol/l, 95% CI 0.10 to 0.39, p = 0.001, respectively). **Conclusions:** RAS Blockades are superior to other antihypertensive agents in improving insulin sensitivity, glycemic control and some metabolic cytokines in non-diabetic patients, indicating a better antihypertensive choice, which probably delays the onsets of diabetes.

Hosted file


manuscript.docx available at <https://authorea.com/users/318792/articles/448806-the-beneficial-effects-of-ras-blockades-on-insulin-sensitivity-metabolic-cytokines-and-glycemic-control-in-non-diabetic-patients-a-meta-analysis>

Hosted file


Table 1.docx available at <https://authorea.com/users/318792/articles/448806-the-beneficial-effects-of-ras-blockades-on-insulin-sensitivity-metabolic-cytokines-and-glycemic-control-in-non-diabetic-patients-a-meta-analysis>



A





B



3

C





	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
AA Lteif 2012	+	+	+	+	+	+	+
Ch. Thirig • L 1995	+	-	+	+	+	+	+
Dilek Yavuz 2003	+	+	-	?	+	+	+
Dongxiu Xu 2007	+	?	?	?	+	+	+
Fabio Belluzzi 2009	+	?	+	+	+	+	+
Francisco J. Martinez-Martin 2011	+	?	-	+	+	+	+
Giuseppe Derosa 2015	+	?	+	+	+	+	+
Grzegorz Piecha 2007	+	?	?	?	+	+	+
Hideki NISHIMURA 2008	+	?	?	?	+	+	+
Jan W. Eriksson 2008	+	+	+	+	+	+	+
Jutta M. Nagel 2006	+	-	+	+	+	+	+
Kwang Kon Koh 2007	+	-	+	+	+	+	+
Kwang Kon Koh 2008	+	?	-	-	+	+	+
Ligia J. Dominguez 1997	+	-	+	+	+	+	+
M. Ivan Wiggam 1998	+	-	+	+	+	+	+
Marta Walczak-Gałe, zewska 2018	+	?	-	-	+	+	+
NYNKE J. VAN DER ZIJL 2011	5+	?	+	+	+	+	+
Robert Krysiak 2008	+	+	+	+	+	+	+
Robert Krysiak 2011	+	+	+	+	+	+	+
Robert Krysiak 2012	+	?	?	?	+	+	+

